Trial findings challenge concerns over early rhythm control in patients with mild to moderate chronic kidney disease (CKD) and recent atrial fibrillation.
Safer and faster procedures may improve recovery times, enhance the patient experience and increase access to treatment.
Atrial fibrillation (AF) is a growing clinical problem associated with increased morbidity and mortality Currently available antiarrhythmic drugs (AADs) can be highly effective in acute cardioversion ...
J&J launches new dual energy catheter ablation solution in Europe: Irvine, California Johnson & Johnson announced the commercial launch of ...
Mental health professionals are trained to be technicians rather than provided with the opportunity to discover the craft of healing.
This 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations for advanced life support includes updates on multiple ...
Nonmedical use of prescription and nonprescription drugs is a worldwide epidemic, rapidly growing in magnitude with deaths because of overdose and chronic use. A vast majority of these drugs are ...
Cardiac electrophysiology (EP) is evolving quickly and data presented this year at ACC.26, European Heart Rhythm Association (EHRA 2026) and Heart Rhythm Society (HRS 2026) suggest practice may change ...
The OCEAN trial may provide the basis for discontinuation of oral anticoagulation following successful catheter ablation of atrial fibrillation, although notably in a patient population who underwent ...
Department of Medicine, Division of Cardiology, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, Ohio, USA Albert L Waldo, MD, Division of Cardiology, Room 3080, Lakeside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results